Kenvue Inc. $KVUE Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 28.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,000,000 shares of the company’s stock after selling 400,048 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.05% of Kenvue worth $17,660,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of KVUE. Johnson Financial Group Inc. purchased a new position in Kenvue during the 2nd quarter valued at $26,000. GK Wealth Management LLC purchased a new stake in Kenvue in the third quarter worth $27,000. CoreCap Advisors LLC increased its stake in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the period. Bell Investment Advisors Inc bought a new stake in shares of Kenvue during the second quarter worth $35,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Kenvue during the third quarter worth $36,000. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

KVUE opened at $19.31 on Thursday. The company has a market capitalization of $37.09 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.06 and a 12-month high of $20.13. The business’s fifty day simple moving average is $18.43 and its 200-day simple moving average is $18.27.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, meeting the consensus estimate of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is presently 95.45%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KVUE. HSBC lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group upped their target price on shares of Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Ten investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $19.29.

Kenvue Company Profile

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.